Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targeted chemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri.

from http://www.kereos.com/

Publications 1 show all

  • 1
    Angiogenesis Inhibitors/therapeutic use
  • 1
    Nanoparticles/therapeutic use
  • 1
    Neoplasms, Experimental/drug therapy
  • 1
    Neovascularization, Pathologic/drug therapy
  • 1
    Prodrugs/therapeutic use
  • 1
    Taxoids/therapeutic use

Patents 68show all

  • 42
    A61K - Preparations for medical, dental, or toilet purposes
  • 15
    B82Y - Specific uses or applications of nanostructures
  • 13
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 5
    B01D - Separation
  • 4
    C07D - Heterocyclic compounds
  • 4
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 2
    C07K - Peptides
  • 2
    C12N - Microorganisms or enzymes
  • 2
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms

SEC Filings show all


4
D

Contact Information

4041 Forest Park Ave.
Saint Louis, MO 63108
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$27,189,9541-102012-01-13Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2009-06-15$887,126Debt Financing
2005-09-20$19,500,000Series BCharter Life Sciences180 Degree Capital, Apjohn ventures, Alafi Capital, Lux Capital, Genentech, MB Venture Partners, Orchard Venture Partners, Triathlon Medical Venture Partners, RiverVest, Koninklijke Philips, Barnes-Jewish Hospital, Prolog Ventures
2012-01-13$1,127,730Series Unknown
2010-05-06$5,675,098Series Unknown

SEC Form D Funding Events

DateOfferedSoldType
2012-01-12$1,127,730$1,127,730Equity
2010-05-06$6,217,618$5,675,098Equity
2009-06-26$887,426$887,126Debt, Option to Acquire
2008-12-10Unknown Unknown Other (Paper Filing)

Key Executives

  • Stephen Snowdy, Ph.D.
    Director
  • Phillip M Buckler
    Executive Officer
  • John M Rice, Ph.D.
    Director
  • Gregory R Johnson, Ph.D.
    Director
  • Fred Schwartzer
    Director
  • Michael Loberg, Ph.D.
    Director
  • Samuel Wickline, M.D.
    Director
  • Phillip M. Buckler
    Executive Officer
  • Gregory R. Johnson, Ph.D.
    Director
  • John Rice, Ph.D.
    Director
  • Fred Schwarzer
    Director
  • Stephen Snowdy
    Director
  • Samuel A. Wickline, M.D.
    Director
  • Gregory R. Johnson, Ph. D.
    Director
  • Michael D. Loberg, Ph. D.
    Director
  • John Rice, Ph. D.
    Director
  • Fred A. Schwarzer, J.D.
    Director
  • Gary Stevenson
    Director